par
John R. Fischer, Senior Reporter | March 12, 2024
Among the therapies it is developing are 177Lu-satoreotide tetraxetan for neuroendocrine tumors, small cell lung cancer, Merkel Cell Carcinoma, and solid tumors; ATT001, which is due to begin Phase I development for the treatment of glioblastoma; ATD001, a fluorine-18 radiolabeled rPARPi currently in Phase I clinical trials at Memorial Sloan Kettering Cancer Center for head and neck cancer; and ATT002 as an alpha and beta therapy.
Its diagnostics pipeline includes NEPHROSCAN, a single-dose kit for the preparation of technetium-99m (Tc-99m) Succimer for renal parenchymal disorders; androgen deprivation therapy for prostate cancer; 68Ga-satoreotide trizoxetan for solid tumors; ATD001 for solid tumors; satoreotide tetraxetan for neuroblastomas.
Ad Statistics
Times Displayed: 2147
Times Visited: 10 Fast-moving cardiac structures have a big impact on imaging. Fujifilm’s SCENARIA View premium performance CT brings solutions to address motion in Coronary CTA while delivering unique dose saving and workflow increasing benefits.
Ariceum has expanded and established its workforce ahead of the lab opening and will recruit additional employees as the company grows. While most early-stage R&D activities will be performed in-house, Ariceum will continue to use external partners for certain aspects of its research and development.
Back to HCB News
